6068-80-0

Usage

Uses

Used in Pharmaceutical Industry:
347TRIMETHOXYQUERCETIN is used as a pharmaceutical agent for its potential therapeutic applications in treating various diseases. Its antioxidant, anti-inflammatory, and anti-cancer properties make it a valuable compound for the development of new medications.
Used in Nutraceutical Industry:
In the nutraceutical sector, 347TRIMETHOXYQUERCETIN is utilized as a dietary supplement ingredient, capitalizing on its health-promoting properties to enhance well-being and support disease prevention.
Used in Antioxidant Applications:
347TRIMETHOXYQUERCETIN serves as a potent antioxidant, protecting cells from oxidative stress and damage, which can contribute to the prevention and treatment of various diseases associated with oxidative stress.
Used in Anti-inflammatory Applications:
Leveraging its anti-inflammatory properties, 347TRIMETHOXYQUERCETIN is applied in reducing inflammation, which is beneficial in managing inflammatory conditions and promoting overall health.
Used in Anti-cancer Applications:
As an anti-cancer agent, 347TRIMETHOXYQUERCETIN is being studied for its ability to inhibit cancer cell growth and proliferation, offering a potential therapeutic strategy in oncology.
Used in Research and Development:
In the realm of research and development, 347TRIMETHOXYQUERCETIN is employed as a subject of study to explore its potential applications and mechanisms of action, furthering our understanding of its role in medicine and healthcare.

InChI:InChI=1/C18H16O7/c1-22-10-7-11(19)15-14(8-10)25-18(17(21)16(15)20)9-4-5-12(23-2)13(6-9)24-3/h4-8,19,21H,1-3H3

Upstream product

• 520-33-2 hesperetin 
• 117-39-5 quercetol 
• 74-88-4 methyl iodide 
• 153-18-4 rutin 
• 24824-54-2 3,4-dimethoxybenzoic anhydride 
• 857617-58-4 2-benzoyloxy-1-(2,6-dihydroxy-4-methoxy-phenyl)-ethanone 

Downstream Products

• 7622-92-6 3,5-diacetoxy-2-(3,4-dimethoxy-phenyl)-7-methoxy-chromen-4-one 

Relevant academic research and scientific papers

Flavonoid compound as well as synthesis method and application thereof

The invention relates to a semi-synthetic flavonoid compound and an anti-inflammatory application thereof. The invention belongs to the technical field of medicines, particularly relates to synthesis of derivatives of natural products and an application of the derivatives in the anti-inflammatory aspect, and more particularly relates to a synthesis method of flavonoid compounds and an application of the flavonoid compounds in the anti-inflammatory aspect. According to the method, hesperetin is taken as a raw material, flavonol aglycone is synthesized, and finally flavonoid glycoside is synthesized through debenzylation and acetyl reaction. According to the invention, 32 flavonoid compounds, including 14 flavonoid aglycones and 18 flavonoid glycosides, including 15 known compounds and 17 unreported compounds, are synthesized in total. The part of the compounds show good in-vitro anti-inflammatory activity and can become anti-inflammatory drugs or lead compounds.

Quercetin analogs with high fetal hemoglobin-inducing activity

β-Thalassemia is the major health problems in developing countries, when affected patients and healthy carriers are numerous, resulting a total absence or severe decrease in the production of β-globin chains. The use of chemical agents for increasing the production of fetal hemoglobin (HbF) by reactivating γ-globin gene to balance excess α-globin chains is an alternative therapeutic approach. Therefore, the search for molecules exhibiting the property of inducing γ-globin gene expression is of great interest. In this report, we discovered that quercetin (1), the major flavonoid isolated from the heartwoods of the medicinal plant Anaxagorea luzonensis promoted the expression of γ-globin gene. Chemical modification of 1 to fourteen methyl ether analogs (2?15) was conducted. The structures of these compounds were established on the basis of their spectroscopic data and by comparison with those of the reported values. The parent flavonoid and its chemically modified analogs were investigated for their γ-globin gene induction for the first time. The parent compound 1 exhibited less induced γ-globin gene expression than cisplatin and hemin, the positive controls. 3,4′-Di-O-methylquercetin (7), the modified analog, significantly enhanced γ-globin gene expression with 2.6-fold change at 8 μM, which was slightly higher than cisplatin and hemin. Moreover, compounds 1 and 7 displayed less cytotoxic activity against K562::ΔGγAγEGFP cells than cisplatin. Structure-activity relationship (SAR) study revealed that the methoxyl groups at the 3- and 4?-positions and the free hydroxyl group at the 7-position are required for strong HbF-inducing activity.

Biological evaluation and SAR analysis of O-methylated analogs of quercetin as inhibitors of cancer cell proliferation

Preclinical Research Using a high-throughout screening approach, the anticancer activities of 16 O-methylated (OMe) analogs of quercetin were assessed. The structure-activity relationships showed that OMe moieties at the 4′ and/or 7 positions were important for maintaining inhibitory activities against the 16 cancer cell lines. Furthermore, when the OH groups at the 3′ and 4′ positions were both replaced by OMe moieties, anticancer activity was enhanced.

Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors

In blood, quercetin is mainly found in metabolized forms. In order to study the activities of these quercetin metabolites in cardiovascular disease, 17 methylquercetin derivatives were synthesized based on metabolism in vivo, their thrombin inhibition activity were evaluated through the analyzation of prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (FIB). The results showed that 6 methylquercetin derivatives had stronger inhibitory activities than that of quercetin. Preliminary SARs analysis showed that hydroxyl groups at C-3′ and C-4′ position in the B-ring and hydroxyl group at C-3 position in the C-ring played key roles in the thrombin inhibitory activity. The findings of this study would provide information for the exploitation and utilization of quercetin as thrombin inhibitor for thrombotic disease treatment.

Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity

The methanolic extracts of several natural medicines and medicinal foodstuffs were found to show an inhibitory effect on rat lens aldose reductase. In most cases, flavonoids were isolated as the active constituents by bioassay-guided separation, and among them, quercitrin (IC50=0.15 μM), guaijaverin (0.18 μM), and desmanthin-1 (0.082 μM) exhibited potent inhibitory activity. Desmanthin-1 showed the most potent activity, which was equivalent to that of a commercial synthetic aldose reductase inhibitor, epalrestat (0.072 μM). In order to clarify the structural requirements of flavonoids for aldose reductase inhibitory activity, various flavonoids and related compounds were examined. The results suggested the following structural requirements of flavonoid: 1) the flavones and flavonols having the 7-hydroxyl and/or catechol moiety at the B ring (the 3′,4′-dihydroxyl moiety) exhibit the strong activity; 2) the 5-hydroxyl moiety does not affect the activity; 3) the 3-hydroxyl and 7-O-glucosyl moieties reduce the activity; 4) the 2-3 double bond enhances the activity; 5) the flavones and flavonols having the catechol moiety at the B ring exhibit stronger activity than those having the pyrogallol moiety (the 3′,4′,5′-trihydroxyl moiety).

Phytochemical Investigation of Cassia spectablis Seeds Isolation and Structural Studies of Two New Flavone Glycosides

From the seeds of Cassia spectablis 6-hydroxy-4'-methoxy flavone-6-O-arabinopyranoside and 3,5-dihydroxy-7,3',4'-trimethoxy flavone-3-O-arabinopyranoside have been isolated and their structure elucidated. - Key words: Cassia Spectablis, Leguminosae, Flavo